Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- General Hospitals' Earnings Up 3 Years in a Row: SWMSC Report
September 2, 2002
- Fujirebio: Half-year Sales Down 4.8% to \12,209 Mil.
September 2, 2002
- 70% of Patients Don't Like Substitutive Generics: Survey
September 2, 2002
- Medical Fee Revision Favors Major Dispensing Pharmacies: Nomura Report
September 2, 2002
- Ivermectin, Micafungin Recommended for Approval by CDFS
September 2, 2002
- MEDICAL DEVICE NEWS IN BRIEF
September 2, 2002
- NHI Price Listing Not Pending for Any More Products
September 2, 2002
- NEW PRODUCTS
September 2, 2002
- Role of "General Manufacturing and Marketing Manager" Needs to Be Clarified
September 2, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
September 2, 2002
- Report Calls For Dosage, Administration in Child Patients
September 2, 2002
- BULLETIN
September 2, 2002
- Korosho Resumes Debates on Production of Blood Products
September 2, 2002
- BUSINESS NEWS IN BRIEF
September 2, 2002
- Human Tissue Transplantation GL Compiled by Society
September 2, 2002
- Janssen's Virtual Hallucination System Used Widely
September 2, 2002
- Monkasho Initiates Protein 3,000 Project
September 2, 2002
- JPMA to Prepare Guidebook on Electronic Data Capture
September 2, 2002
- REGULATORY NEWS IN BRIEF
September 2, 2002
- CMIC to Expand Business in Response to New PAL
September 2, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…